Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cytotoxicity of Yellow Fever specific CD8 T cells Following YF-17D Vaccination
2019-001731-31Phase 4Completed
- Sponsor
- Aarhus University Hospital
- Start
- Jun 2019
- Modality
- Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of 17D yellow fever vaccine in yellow fever, sponsored by Aarhus University Hospital. Primary endpoint: Cytotoxicity of NS4B 214-222-specific CD8+ T cells. Started Jun 2019; status: completed.
02
Drugs
17D yellow fever vaccine
03
Conditions
yellow fever
Beyond the preview
Go deeper on 2019-001731-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001731-31.